Medical Devices Investors & VC Firms in Seattle
13 firms in this list, with a median first check of $500K. 4 of them lead rounds. Generated from verified public data and updated continuously.
Frazier Healthcare Partners
SeattleGrowth$50M – $400M
51 people
SPRINGROCK VENTURES
SeattleSeed–Late Stage$2M – $5M
16 people
Remiges Ventures, Inc.
SeattlePre-Seed–Seed
22 people
WRF Capital
SeattlePre-Seed–Series B$100K – $2M
21 people
Allumia Ventures
SeattleSeries A–Late Stage$5M – $15M
12 people
Swan Venture Fund
SeattlePre-Seed–Seed$200K – $1.2M
5 people
Pave Health Ventures
SeattlePre-Seed–Series A
11 people
Zoic Capital
SeattleSeed–Series A
12 people
Anthropy Partners
SeattlePre-Seed–Series A
6 people
The W Fund
SeattlePre-Seed–Series A$500K
Sahsen Ventures
SeattlePre-Seed–Series A
5 people
RDiscovery
TokyoPre-Seed–Series A
20 people
Fox Ventures
ChampaignSeed–Late Stage$50K – $250K
7 people
Frequently asked questions
- Who are the top medical devices investors & vc firms in seattle?
- Top medical devices investors & vc firms in seattle include Frazier Healthcare Partners, SPRINGROCK VENTURES, Remiges Ventures, Inc., WRF Capital, Allumia Ventures, Swan Venture Fund, Pave Health Ventures, Zoic Capital — 13 firms in total meet the criteria.
- What is the typical first check among medical devices investors & vc firms in seattle?
- The median first check among the 13 medical devices investors & vc firms in seattle tracked here is $500K.
- How many medical devices investors & vc firms in seattle lead rounds?
- 4 of the 13 medical devices investors & vc firms in seattle tracked here lead investment rounds.
Related lists
Investors & VC Firms in North America (14143)Investors & VC Firms in United States (13281)Investors & VC Firms in Europe (5575)Crypto & Web3 Investors & VC Firms (4830)Investors & VC Firms in Global (4158)SaaS Investors & VC Firms (3865)AI & Machine Learning Investors & VC Firms (3769)Fintech Investors & VC Firms (3726)Investors & VC Firms in Asia-Pacific (3574)Healthtech Investors & VC Firms (3415)
Data sourced from public filings and firms' own websites — see our methodology.






































